Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published by WILEY, stands at the forefront of research in the fields of neurology and psychiatry. As an Open Access journal since 2015, it fosters transparency and accessibility in sharing critical knowledge pertaining to the diagnosis, assessment, and monitoring of Alzheimer’s disease and related dementias. With an impressive impact factor reflected in its Q1 rankings in both Neurology (Clinical) and Psychiatry and Mental Health, this journal is recognized for its significant contribution to advancing understanding and improving clinical practices, as evidenced by its Scopus rankings in the top percentiles. Researchers, healthcare professionals, and students are encouraged to engage with the latest findings and methodologies that shape the future of dementia care, enhancing both patient outcomes and the scientific community's response to this pressing health challenge. With its headquarters located in Hoboken, NJ, this journal is a pivotal platform for disseminating high-quality, peer-reviewed research that strives to combat one of the most challenging areas in medicine today.

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

Alzheimer's & Dementia: Translational Research & Clinical Interventions, published by WILEY, is a premier open-access journal that has been at the forefront of innovations in the field of neurology and psychiatry since its inception in 2015. With an impressive impact factor reflecting its high-quality research contributions, this journal has been designated as Q1 in both Neurology (Clinical) and Psychiatry and Mental Health categories for 2023, ranking in the top percentiles of their respective Scopus fields. The journal aims to bridge the gap between research and clinical practice, promoting the translation of scientific discoveries into real-world applications for Alzheimer's disease and other dementias. Positioned in the United States, it is a valuable resource for researchers, clinicians, and students dedicated to advancing knowledge and treatment approaches in these critical areas. With its commitment to open access, the journal ensures that vital research is accessible to a broad audience, fostering collaboration and knowledge sharing across the global scientific community.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

Journal of Alzheimer's Disease, published by IOS Press, stands as a pivotal resource in the fight against Alzheimer's and related neurodegenerative disorders. With an ISSN of 1387-2877 and an E-ISSN of 1875-8908, this esteemed journal has evolved since its inception in 1998, providing a vital platform for academic research and clinical practice in the realms of Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Ranked in the Q1 category across several disciplines, including Clinical Psychology and Geriatrics, this journal not only highlights significant advancements in understanding Alzheimer's disease but also fosters interdisciplinary dialogue among researchers, healthcare professionals, and policymakers. Boasting robust Scopus rankings—such as 49th in Clinical Psychology and 29th in Geriatrics—this journal is committed to disseminating high-quality research that informs both therapeutic strategies and public health initiatives. The Journal of Alzheimer's Disease is an essential resource for anyone dedicated to exploring the complexities of cognitive decline and enhancing care for affected individuals.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

AGEING RESEARCH REVIEWS, published by Elsevier Ireland Ltd, is a prestigious academic journal dedicated to advancing our understanding of the biological, psychological, and societal aspects of aging. With an ISSN of 1568-1637 and E-ISSN of 1872-9649, this journal has established itself as a leading resource in the fields of Aging, Biochemistry, Biotechnology, Molecular Biology, and Neurology, consistently ranked in the Q1 category across these disciplines as of 2023. For researchers, students, and professionals eager to explore cutting-edge findings and innovative methodologies, AGEING RESEARCH REVIEWS gathers comprehensive reviews that facilitate a deeper understanding of age-related processes. Its high impact factor and exceptional Scopus rankings—ranking #1 in Aging and #3 in Neurology—underscore its critical role in shaping contemporary aging research. This journal not only serves as a vital reference point but also fosters a collaborative space for the scientific community focused on improving health outcomes across the life span. Published continuously since 2002 and with a converging focus through 2024, AGEING RESEARCH REVIEWS remains committed to disseminating impactful knowledge that drives progress in our understanding of the aging process.